Share on StockTwits

BioTelemetry (NASDAQ:BEAT) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a note issued to investors on Monday, AnalystRatings.Net reports. The firm currently has a $9.20 target price on the stock. Zacks‘ price objective points to a potential upside of 5.99% from the company’s current price.

A number of other firms have also recently commented on BEAT. Analysts at Benchmark Co. reiterated a “buy” rating on shares of BioTelemetry in a research note on Monday, February 3rd. They now have a $15.00 price target on the stock. Finally, analysts at Dougherty & Co reiterated a “buy” rating on shares of BioTelemetry in a research note on Wednesday, December 4th.

BioTelemetry (NASDAQ:BEAT) traded up 2.97% on Monday, hitting $8.68. The stock had a trading volume of 247,857 shares. BioTelemetry has a 52 week low of $2.30 and a 52 week high of $11.88. The stock has a 50-day moving average of $8.08 and a 200-day moving average of $8.83. The company’s market cap is $223.6 million.

BioTelemetry, Inc (NASDAQ:BEAT), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services.

To view Zacks’ full report, visit

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.